MicroPort Scientific Corporation provided consolidated earnings guidance for the six months ended June 30, 2022. For the six months, the Group recorded loss attributable to equity shareholders of the Company of between approximately USD 193 million and USD 203 million, as compared with a loss of approximately USD 90.3 million for the same period last year. This change was principally attributable to (i) the increase in non-cash expenses, including the accrued interest on the convertible bonds issued by the Group and the preference shares issued by subsidiaries, the increase in costs recognized for the incentive shares and underlying shares granted to certain employees under the Group's share incentive schemes, as well as the effect of widening losses of equity-accounted investees during the Reporting Period; (ii) significant increases in expenses for the surgical robot business, the heart valve business, the surgical business and other business segments in their active promotion of research and development, registration and commercialization with the help of their own independent financing channels; and (iii) increase in investment in overseas market development and product promotion.